SALL4 and neoplasm: Moreover, SALL4- and NY-ESO-1-specific T cell responses in patients with a low tumour burden (53.86 ± 18.3 SFUs/106 cells and 16.88 ± 8.03 SFUs/106 cells, respectively) were significantly higher than those in patients with a high tumour burden (25.59 ± 14.46 SFUs/106 cells and 0, respectively; P = 0.0102 and P = 0.0461, respectively; Fig. 5A).